News & Updates

Show Multimedia Only
One-off prison-based HCV screening cost-effective, reduces cirrhosis, HCC, and HCV-related mortality
One-off prison-based HCV screening cost-effective, reduces cirrhosis, HCC, and HCV-related mortality
07 May 2026 byNatalia Reoutova

A University of Hong Kong analysis shows one-off hepatitis C virus (HCV) screening of persons in custody (PICs) to be cost-effective and reduce the rates of HCV-related compensated and decompensated cirrhosis (DC), hepatocellular carcinoma (HCC), and HCV-related mortality.

One-off prison-based HCV screening cost-effective, reduces cirrhosis, HCC, and HCV-related mortality
07 May 2026
Enzalutamide plus leuprolide delays metastasis, progression in prostate cancer
Enzalutamide plus leuprolide delays metastasis, progression in prostate cancer
06 May 2026 byStephen Padilla

Prostate cancer patients treated with enzalutamide plus leuprolide have a higher probability of remaining free of distant metastasis, castration resistance, symptomatic progression, and first symptomatic skeletal event (SSE) at 5 years than those treated with leuprolide alone, as shown by the results of the EMBARK study.

Enzalutamide plus leuprolide delays metastasis, progression in prostate cancer
06 May 2026